
Biogen (BIIB) Stock Forecast & Price Target
Biogen (BIIB) Analyst Ratings
Bulls say
Biogen is poised for growth due to the success of its commercial execution, with strong revenue beats in the first quarter of 2026 and a favorable tax rate. Its newer franchises are also showing promise, with potential for further growth in the future. Key upcoming catalysts and strategic initiatives, such as the APLS acquisition and pipeline updates, will likely contribute to its long-term success and justify a BUY rating. However, potential risks include slower-than-expected sales ramp and competition from other biopharmaceutical companies.
Bears say
Biogen is facing several challenges and uncertainties, such as declining revenue from its multiple sclerosis franchise, competition in the market, and potential pipeline setbacks. While the company is actively pursuing treatments for high unmet needs in neurodegenerative diseases, it remains to be seen if these therapies will be successful in the market. Additionally, the company's sustainability initiatives and employee engagement are commendable, but may not necessarily translate into financial success. Overall, there are concerns about the long-term growth potential of the company and risks associated with its pipeline.
This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.
Biogen (BIIB) Analyst Forecast & Price Prediction
Start investing in Biogen (BIIB)
Order type
Buy in
Order amount
Est. shares
0 shares